Comparing the current results to its competitors, Chemomab Therapeutics Ltd reported Revenue decrease in the 4 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 4.31 %, recorded in the same quarter.
Chemomab Therapeutics Ltd 's Comment on Competition and Industry Peers
The competitive landscape for primary sclerosing cholangitis (PSC) includes companies developing treatments, with no FDA-approved therapies currently available. Dr. Falk Pharma is conducting Phase 3 clinical studies focusing on cholestasis and liver metabolism with norUrso. Ipsen Pharmaceuticals is preparing a Phase 3 trial of Elafibranor targeting bile acid metabolism. Mirum Pharmaceutical has candidates in earlier development stages. Most competitors address metabolic or symptomatic aspects of PSC, while Chemomab's nebokitug is noted for potential disease-modifying effects through dual anti-fibrotic and anti-inflammatory activity.
For systemic sclerosis (SSc), two FDA-approved products exist: nintedanib by Boehringer Ingelheim GmbH and tocilizumab by Hoffmann-La Roche. Early-stage clinical development for SSc involves companies including Amgen, Merck, GSK, and Boehringer Ingelheim. Factors such as reimbursement availability and regulatory approval timelines may influence competitiveness and market positioning.
Competitors identified include Amgen, Boehringer Ingelheim GmbH, Chemomab, Dr. Falk Pharma, GSK, Hoffmann-La Roche, Ipsen Pharmaceuticals, Merck, and Mirum Pharmaceutical.
March 3, 2025
Abstract: Chemomab Therapeutics Ltd. recently announced its financial results for the fourth quarter and the year ended 2024, revealing mixed outcomes regarding its performance relative to competitors in the pharmaceutical sector. While the company reported promising results from its Phase 2 trial for nebokitug in primary sclerosing cholangitis, its financial figures indicate a decline in revenue and net income compared to its competitors.Chemomab Therapeutics Ltd., a biopharmaceutical company focused on developing treatments for fibrotic diseases, recently issued its financial results for Q4 2024 and provided updates on its product development pipeline. The report highlights both encouraging clinical findin...
November 19, 2024
Unlocking New Frontiers in Primary Sclerosing Cholangitis: The Promise of Chemomabs CM-101 Recent research presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024 has showcased the compelling potential of Chemomab Therapeutics CM-101 in treating Primary Sclerosing Cholangitis (PSC), a rare and chronic liver disease characterized by progressive inflammation and scarring of the bile ducts. The oral presentation highlighted the broad clinical activity of CM-101 across multiple biomarkers and its potential to modify the course of PSC fundamentally. Clinical Insights into CM-101 Chemomab s CM-101 is a monoclonal antibody designed to target and modulate the activity of...
July 25, 2024
Chemomab Therapeutics has recently made significant strides in the quest for effective treatments for fibrotic diseases, particularly Primary Sclerosing Cholangitis (PSC) and systemic sclerosis. The company has released promising topline data from its Phase 2 clinical trial of CM-101, a novel therapeutic intervention targeting disease mechanisms linked to fibrotic conditions, alongside new insights that underscore the role of the CCL24 protein in systemic sclerosis. Positive Phase 2 Trial Results for CM-101 in Primary Sclerosing CholangitisIn a major development, Chemomab announced the successful completion of its Phase 2 clinical trials for CM-101, assessing its efficacy and safety for treating PSC, a chro...
June 6, 2024
Novel Therapeutic Approach for Primary Sclerosing Cholangitis: CM-101 Shows Promise in Clinical Data Presented by Chemomab Therapeutics Chemomab Therapeutics is making waves in the field of hepatology with its innovative therapeutic candidate CM-101, aimed at treating Primary Sclerosing Cholangitis (PSC). At the European Association for the Study of the Liver (EASL) 2024 meeting and a subsequent Gordon Research Conference, the company unveiled promising data that could redefine the treatment landscape for this chronic liver disease. Primary Sclerosing Cholangitis (PSC) presents a formidable challenge in the realm of hepatology, characterized by inflammation and fibrosis of the bile ducts, eventually leadin...
March 25, 2024
In a significant development, Chemomab has been granted a new European patent for its groundbreaking monoclonal antibody, CM-101. This patent extension further strengthens Chemomab s intellectual property portfolio in several territories and highlights the potential of CM-101 as a therapeutic intervention for liver diseases, particularly Primary Sclerosing Cholangitis (PSC). This article aims to analyze the recently awarded European patent and its implications for the ongoing Phase 2 clinical trials of CM-101.Background:Primary Sclerosing Cholangitis is a chronic liver disease characterized by progressive inflammation and fibrosis of the bile ducts, ultimately leading to liver failure. Currently, there are ...
Publicly Traded Peers of Chemomab Therapeutics Ltd
Akero Therapeutics Inc Share Performance
+76.23%
One Year
Akero Therapeutics Inc
Profile
Akero Therapeutics Inc is a biotechnology company that focuses on the development of breakthrough treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders. Their business model revolves around advancing their proprietary drug candidates through preclinical and clinical stages to ultimately bring them to market, partnering with leading academic institutions and leveraging scientific expertise to drive innovation in the field. Akero Therapeutics aims to address the significant unmet medical needs in these areas and create value for patients, healthcare providers, and shareholders.
Biolinerx Ltd is a biopharmaceutical company that focuses on discovering, developing, and commercializing novel therapeutics for various diseases. Their business model revolves around the research and development of innovative drug candidates, conducting clinical trials to assess their safety and efficacy, and obtaining regulatory approvals to bring these treatments to market. They aim to generate revenue through licensing agreements, strategic collaborations, and the sale of their therapeutics to patients or healthcare providers.
Edesa Biotech Inc's business model focuses on the development and commercialization of innovative therapeutics in the field of dermatology and gastrointestinal diseases.
Galmed Pharmaceuticals Ltd's business model focuses on the development and commercialization of innovative therapeutic solutions, particularly in the field of liver and metabolic diseases.
Sources:
Chemomab Therapeutics Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Chemomab Therapeutics Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
